Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
99mTc-EDDA-KL01099 is an experimental **PSMA-targeted radiopharmaceutical** imaging agent for prostate cancer detection by SPECT. It is a **technetium-99m-labeled small-molecule tracer** built on a Lys-urea-Glu PSMA-binding pharmacophore conjugated to a HYNIC chelator and formulated with EDDA as a co-ligand for technetium coordination. In preclinical studies, the tracer bound PSMA-expressing cells with nanomolar affinity and visualized PSMA-positive prostate cancer xenografts in SPECT imaging, but also showed relatively high renal and splenic uptake. Based on the provided literature context, it appears to be a research-stage academic radiotracer rather than a commercial product, investigated for molecular imaging of prostate cancer lesions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 99mTc-EDDA-KL01099.